Osteoarthritis (OA) continues to be a major health burden in India, affecting nearly 22% to 39% of the population. Patients often struggle with limited treatment options that primarily address symptoms rather than the underlying pathology. However, recent research has introduced a promising HSP90β osteoarthritis therapy using a methyl gallate and hyaluronic acid-nanoconjugate. Because of this high disease prevalence, this innovative approach targets the heat shock protein 90β (HSP90β) to significantly reduce cartilage inflammation and degeneration.

Specifically, researchers identified methyl gallate (MG) as a potent agent that delays OA progression by protecting chondrocytes. By utilizing drug affinity responsive target stability assays, they discovered that MG directly interacts with HSP90β. Moreover, clinical data from 53 patients further supports this, showing a direct link between high HSP90β levels and increased pain scores. Consequently, silencing this protein reduces the expression of harmful inflammatory markers like IL-6 and matrix metalloproteinases. In addition to these cellular benefits, the therapy blocks the PI3K/Akt pathway effectively.

Advancements in HSP90β Osteoarthritis Therapy

To improve clinical outcomes, scientists conjugated MG with hyaluronic acid (HA) using a reduction-responsive disulfide linker. Furthermore, this HA-MG nanoconjugate ensures better retention within the joint cavity compared to free MG. Similarly, in-situ imaging confirmed that the conjugate accumulates more effectively in the joint. Therefore, this targeted delivery system enhances therapeutic efficacy while minimizing systemic side effects. As a result, this polysaccharide-based approach represents a significant step forward in disease-modifying OA treatments. For instance, the long-term retention in the joint cavity allows for sustained drug release.

What makes HSP90β a suitable target for OA?

HSP90β is upregulated in osteoarthritic cartilage and correlates with pain severity. By inhibiting this protein, clinicians can potentially reduce the PI3K/Akt pathway activity and lower the production of inflammatory cytokines.

How does the HA-MG nanoconjugate improve treatment?

The nanoconjugate uses hyaluronic acid to target the joint specifically. The disulfide linker allows for controlled release, ensuring that the drug stays in the joint cavity longer than traditional injections, which improves cartilage protection.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Always consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Shen A et al. Methyl gallate and hyaluronic acid-nanoconjugate targeting HSP90β for osteoarthritis therapy. J Nanobiotechnology. 2026 Mar 07. doi: 10.1186/s12951-026-04239-y. PMID: 41795076.

Hazra S et al. Prevalence of Knee Osteoarthritis in India: A Systematic Review and Meta-Analysis of Population-Based Studies. PubMed 2025.

Correa LB et al. Protective Effect of Methyl gallate on Murine Antigen-Induced Arthritis by Inhibiting Inflammatory Process and Bone Erosion. ResearchGate 2021.